GGrantIndex
← Leaderboards

D Craig Allred

Baylor College Of Medicine

$2,257,762
Attributed
$2,257,762
Total exposure
7
Grants
1
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $276.3K · FY200508
$500K$375K$250K$125K$0
'05
'06
'07
'08

Funding mix

By agency

NIH$2,257,762 · 7

By mechanism

P01$1,424,592 · 4
P30$639,822 · 1
U19$193,348 · 1
P50$0 · 1

Top collaborators

No co-investigators on record.

Most similar at Baylor College Of Medicine

Same institution · by research overlap

Others in their field

Top investigators on “Breast Neoplasms

Research focus

Breast NeoplasmsImmunocytochemistryHistopathologyHuman TissueCancer RiskGrowth FactorPrognosisBiomedical FacilityOncogenesGene ExpressionNeoplasm /Cancer Remission /RegressionTissue /Cell PreparationCarcinogenesis InhibitorCell CycleHuman SubjectDissectionPreneoplastic StateBiomarkerChemopreventionNeoplasm /Cancer ChemotherapyCancer PreventionTamoxifenBiopsyWestern Blottings

Grant awards (25)

Core--Pathology and Tissue Resource$276,322
P01 · FY2008 · CA · contact PI
Core--Pathology and Tissue Resource$275,571
P01 · FY2007 · CA · contact PI
Core--Pathology and Tissue Resource$174,034
P01 · FY2006 · CA · contact PI
Core--Pathology and Tissue Resource$170,059
P01 · FY2005 · CA
Core--Pathology and Tissue Resource$165,632
P01 · FY2004 · CA
CORE--PATHOLOGY$254,104
P30 · FY2002 · CA
DEVELOPMENTAL &PROGNOSTIC FACTORS IN PREMALIGNANT BREAST DISEASE$0
P01 · FY2002 · CA
CORE--MICRODISSECTION$0
P01 · FY2002 · CA
CORE--HISTOPATHOLOGY$0
P01 · FY2002 · CA
BIOMARKERS AS SURROGATE ENDPOINTS--TAMOXIFEN FOR BREAST CANCER CHEMOPREVENTION$0
P50 · FY2002 · CA
BIOMARKERS AS SURROGATE ENDPOINTS--TAMOXIFEN FOR BREAST CANCER CHEMOPREVENTION$0
P50 · FY2002 · CA
BIOMARKERS AS SURROGATE ENDPOINTS--TAMOXIFEN FOR BREAST CANCER CHEMOPREVENTION$0
P50 · FY2002 · CA
CORE--PATHOLOGY$0
U19 · FY2002 · CA
CORE--PATHOLOGY$254,104
P30 · FY2001 · CA
DEVELOPMENTAL &PROGNOSTIC FACTORS IN PREMALIGNANT BREAST DISEASE$0
P01 · FY2001 · CA
CORE--PATHOLOGY$0
U19 · FY2001 · CA
CORE--MICRODISSECTION$0
P01 · FY2001 · CA
BIOMARKERS AS SURROGATE ENDPOINTS--TAMOXIFEN FOR BREAST CANCER CHEMOPREVENTION$0
P50 · FY2001 · CA
BIOMARKERS AS SURROGATE ENDPOINTS--TAMOXIFEN FOR BREAST CANCER CHEMOPREVENTION$0
P50 · FY2001 · CA
CORE--PATHOLOGY$193,348
U19 · FY2000 · CA
DEVELOPMENTAL &PROGNOSTIC FACTORS IN PREMALIGNANT BREAST DISEASE$181,487
P01 · FY2000 · CA
CORE--MICRODISSECTION$181,487
P01 · FY2000 · CA
CORE--PATHOLOGY$131,614
P30 · FY2000 · CA
BIOMARKERS AS SURROGATE ENDPOINTS--TAMOXIFEN FOR BREAST CANCER CHEMOPREVENTION$0
P50 · FY2000 · CA
BIOMARKERS AS SURROGATE ENDPOINTS--TAMOXIFEN FOR BREAST CANCER CHEMOPREVENTION$0
P50 · FY2000 · CA